Time to capitalise on Hikma’s ongoing (share price) momentum
17/05/24 -"We have incorporated higher royalty payments in 2024 related to the sale of the generic version of sodium oxybate (medicine to treat symptoms of narcolepsy, i.e. sudden muscle weakness and excessive ..."
Pages
50
Language
English
Published on
17/05/24
You may also be interested by these reports :
20/01/26
Virbac ended 2025 on a strong note, with sales growth (at CERS) exceeding the management’s guidance that was upgraded only in October 2025. The ...
15/01/26
In late-2024, when we last teased the story of DiaSorin (BUY; Italy), a family-owned in-vitro diagnostic company specialising in immunodiagnostics ...
09/01/26
Hikma, over the years, has struggled to create shareholder wealth, perhaps because of its inability (until now) to develop biosimilars on its own. ...
31/12/25
Keeping in mind the underwhelming late-stage results of the immunology drug, amlitelimab, and a few other R&D setbacks in recent years, we have ...